SARC028: pembrolizumab in advanced soft tissue and bone sarcoma
Pembrolizumab had little effect in most sarcomas, but it shrank tumours in about 40 percent of patients with undifferentiated pleomorphic sarcoma and some with dedifferentiated liposarcoma, singling out these subtypes for immunotherapy.
Overview
Phase 2 study of 86 patients with advanced soft tissue sarcoma (undifferentiated pleomorphic sarcoma, dedifferentiated liposarcoma, synovial sarcoma, leiomyosarcoma) or bone sarcoma treated with pembrolizumab.
Objective response was 18 percent in soft tissue sarcoma, driven by 40 percent in undifferentiated pleomorphic sarcoma and 20 percent in dedifferentiated liposarcoma, with no responses in leiomyosarcoma and one in synovial sarcoma; bone sarcoma response was 5 percent.
- Objective response 40 percent in undifferentiated pleomorphic sarcoma; 20 percent in dedifferentiated liposarcoma.
- 0 percent in leiomyosarcoma; 5 percent in bone sarcomas.
PD-1 blockade is an off-label or trial option specifically for undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma, not for sarcoma in general.
- Small cohorts of about 10 patients per histology; expansion cohorts confirmed lower rates (about 23 percent) in undifferentiated pleomorphic sarcoma.
Similar pages
not linked directly; found by shared links- Key paperISG-STS 1001: histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in high-risk soft tissue sarcoma
Shares Undifferentiated pleomorphic sarcoma (UPS), The Lancet Oncology.
- Key paperKEYNOTE-859: pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer
Shares The Lancet Oncology, Pembrolizumab.
- Key paperKEYNOTE-057: pembrolizumab for BCG-unresponsive non-muscle-invasive bladder cancer with carcinoma in situ
Shares The Lancet Oncology, Pembrolizumab.
- Key paperEORTC 62012: doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced soft tissue sarcoma
Shares Undifferentiated pleomorphic sarcoma (UPS), The Lancet Oncology.
- CancerLiposarcoma